205 related articles for article (PubMed ID: 14991374)
1. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
Müller N; Ulmschneider M; Scheppach C; Schwarz MJ; Ackenheil M; Möller HJ; Gruber R; Riedel M
Eur Arch Psychiatry Clin Neurosci; 2004 Feb; 254(1):14-22. PubMed ID: 14991374
[TBL] [Abstract][Full Text] [Related]
2. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
Müller N; Riedel M; Scheppach C; Brandstätter B; Sokullu S; Krampe K; Ulmschneider M; Engel RR; Möller HJ; Schwarz MJ
Am J Psychiatry; 2002 Jun; 159(6):1029-34. PubMed ID: 12042193
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Akhondzadeh S; Tabatabaee M; Amini H; Ahmadi Abhari SA; Abbasi SH; Behnam B
Schizophr Res; 2007 Feb; 90(1-3):179-85. PubMed ID: 17208413
[TBL] [Abstract][Full Text] [Related]
4. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.
Nery FG; Monkul ES; Hatch JP; Fonseca M; Zunta-Soares GB; Frey BN; Bowden CL; Soares JC
Hum Psychopharmacol; 2008 Mar; 23(2):87-94. PubMed ID: 18172906
[TBL] [Abstract][Full Text] [Related]
7. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib augmentation of continuously ill patients with schizophrenia.
Rapaport MH; Delrahim KK; Bresee CJ; Maddux RE; Ahmadpour O; Dolnak D
Biol Psychiatry; 2005 Jun; 57(12):1594-6. PubMed ID: 15953498
[TBL] [Abstract][Full Text] [Related]
9. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of COX-2 inhibitors on cognition in schizophrenia.
Müller N; Riedel M; Schwarz MJ; Engel RR
Eur Arch Psychiatry Clin Neurosci; 2005 Apr; 255(2):149-51. PubMed ID: 15549344
[TBL] [Abstract][Full Text] [Related]
11. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
12. [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia].
Lü LX; Guo SQ; Chen W; Li Q; Cheng J; Guo JH
Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1251-4. PubMed ID: 15567770
[TBL] [Abstract][Full Text] [Related]
13. Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders.
Müller N; Riedel M; Schwarz MJ
Pharmacopsychiatry; 2004 Nov; 37(6):266-9. PubMed ID: 15551192
[TBL] [Abstract][Full Text] [Related]
14. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
[TBL] [Abstract][Full Text] [Related]
15. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.
Lee BH; Kim YK
Neuropsychobiology; 2009; 59(1):51-8. PubMed ID: 19270464
[TBL] [Abstract][Full Text] [Related]
17. Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia.
Yokota O; Terada S; Ishihara T; Nakashima H; Kugo A; Ujike H; Tsuchiya K; Ikeda K; Saito Y; Murayama S; Ishizu H; Kuroda S
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):715-21. PubMed ID: 15276698
[TBL] [Abstract][Full Text] [Related]
18. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines.
Pae CU; Yoon CH; Kim TS; Kim JJ; Park SH; Lee CU; Lee SJ; Lee C; Paik IH
Int Immunopharmacol; 2006 Apr; 6(4):666-71. PubMed ID: 16504930
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
Himei A; Okamura T
Psychiatry Clin Neurosci; 2005 Oct; 59(5):556-62. PubMed ID: 16194258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
